NY-EGON-ZEHNDER
19.11.2020 06:02:11 CET | Business Wire | Press release
Egon Zehnder, the world’s leadership advisory firm, and Out Leadership, the first and only global platform for CEOs and multinational companies to advocate for LGBTQ+ inclusion and equality, today announce a partnership aimed at promoting LGBTQ+ representation at senior levels of business.
Egon Zehnder will be the newest member of Out Leadership’s coalition, which includes such companies as P&G, Publicis Sapient, Goldman Sachs, Microsoft, Mastercard, National Australia Bank, Nomura, KPMG, Citi, Coca Cola, Dow Chemical, and LVMH. The two firms will work together on advisory and executive search services, thought leadership and events, with the goal of building a more robust pipeline for senior leadership positions and Board appointments. Per the agreement, Egon Zehnder will become a member of Out Leadership's business network and will be the exclusive search firm partner/sponsor of Quorum, Out Leadership’s brand covering all events and thought leadership initiatives related to promoting LGBT representation on corporate boards.
“At Egon Zehnder, we understand that diversity of background and thought is an imperative for business success,” says Jill Ader, Chair, Egon Zehnder. “We are thrilled to partner with Out Leadership on our joint commitment to ensure that the LGBTQ+ community is represented at the top levels of business and elsewhere in society.”
"The push for broader diversity on boards globally has too often excluded LGBTQ leaders, both in policy, placement and practice,” says Todd Sears, Founder and CEO of Out Leadership. “Out Leadership, and our Quorum initiative, have been striving since 2010 to increase LGBTQ inclusivity--especially at the board level where the greatest impact often is made. We're proud to have Egon Zehnder as our newest partner and the first of the major leadership advisory firms to recognize the importance of LGBTQ diversity both in the U.S. and around the world.”
The first joint effort between the two firms will involve the copromotion of Egon Zehnder’s Global Board Diversity Tracker, which will be released December 8th and which for the first time will involve analysis beyond gender, including research provided by Out Leadership. Ultimately the two organizations will develop proprietary research, events, and other joint projects.
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, sharing one goal: to help people and organizations transform. We know what great leaders can do and are passionate about delivering the best solutions for our clients. At Egon Zehnder, we passionately believe that diverse and inclusive leaders are able to create a better world where individuals and organizations not only grow; they thrive. It is central to our core values and fundamental belief that organizations deliver better performance when diverse voices are heard and individuals feel they belong. For this reason, Egon Zehnder is committed to celebrating, supporting and advocating for the LGBTQ+ community globally.
As One Firm, our more than 500 Consultants in 68 offices and 40 countries combine our individual strengths to form one powerful collaborative team. We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide a comprehensive range of integrated services: Board advisory, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.
Our leadership solutions cover individual, team and organizational effectiveness, development and cultural transformation. We work with world-class partners including Mobius Executive Leadership, a transformational leadership development firm. In addition, we have partnered with Paradox Strategies, co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic.
Our goal is that the work we do contributes to successful careers, stronger companies – and a better world.
For more information, visit www.egonzehnder.com and follow us on LinkedIn and Twitter .
About Out Leadership:
Out Leadership is the oldest and largest global LGBTQ+ business advisory that partners with the world’s most influential companies to build business opportunities, cultivate talent, and drive LGBTQ+ equality forward. We believe that LGBTQ+ inclusion positively impacts business results, and that including LGBTQ+ people at the most senior level of executive leadership builds business. We call this idea Return on Equality™.
Comprising 85 global member firms and dedicated to cross-industry collaboration, Out Leadership is a certified B Corporation. Out Leadership convenes CEOs, business leaders and allies at exclusive invitation only events across 4 continents. Out Leadership also operates three talent initiatives: Quorum, which aims to increase LGBTQ+ representation on corporate boards; OutNEXT, the first global talent development program for emerging LGBTQ+ leaders; and OutWOMEN, connecting senior level LGBTQ+ women in business. To learn more, please visit https://outleadership.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118006001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
